Group ACYW135 Meningococcal Conjugate Vaccine (CRM197)

Meningococcal conjugate vaccine (CRM197) for groups A, C, W-135, Y · CanSino Biologics Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Group ACYW135 Meningococcal Conjugate Vaccine (CRM197), covering 2025-04-03 to 2025-04-03. Get the full timeline:

Most recent: Clinical Trial Update: A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years [Phase 3]

See pricing